Onconova technologies and products are developed utilizing our proprietary chemistry platform. Our capabilities span drug discovery and early development stages, from medicinal chemistry to Phase 3 clinical trials. Some of our product candidates are partnered with pharmaceutical or biotechnology companies for advanced development. We endeavor to retain a participating role as we expand our competency horizon to include commercialization capabilities.
To discuss partnering opportunities with Onconova, please contact us at: firstname.lastname@example.org
SYMBIO PHARMACEUTICALS LIMITED
July 2011 – Onconova and SymBio Pharmaceuticals began a collaboration to develop and commercialize rigosertib in Japan and Korea. Under the terms of the agreement, SymBio has an exclusive license for Japan and Korea and will develop and commercialize rigosertib in these countries. Onconova received an upfront payment and will receive milestone payments tied to the progress of rigosertib development, as well as sales milestone payments plus royalties on net sales. Onconova supplies drug product for clinical trials conducted by SymBio in Japan.
HanX Biopharmaceuticals, Inc.
May 10, 2019 – Onconova entered into a License Agreement with HanX Biopharmaceuticals to develop and commercialize Rigosertib in Greater China
For more information please refer to the Press Release of May 13, 2019
Dec 19, 2017 – Onconova entered into a License and Collaborative Development Agreement with HanX Biopharmaceuticals, Inc. for the further development, registration, and commercialization of ON 123300 in China. ON 123300 is a first-in-class dual inhibitor of CDK4/6 + ARK5, which is currently in advanced pre-clinical development. This compound has the potential to overcome the limitations of current generation CDK 4/6 inhibitors.
For more information please refer to the Press Release of Dec. 19, 2017
NATIONAL CANCER INSTITUTE/NATIONAL INSTITUTES OF HEALTH
Jan 04, 2018 – Onconova entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under the terms of the CRADA, the NCI will conduct research, including preclinical laboratory studies and a clinical trial, on rigosertib in pediatric cancer associated RASopathies.
For more information please refer to the Press Release of Jan. 4, 2018
March 5, 2018 – Onconova entered into a License Agreement with Pint Pharma GmbH to commercialize rigosertib in Latin America. Pint Pharma is a Europe based pharmaceutical company focused on the development, registration and commercialization of specialty-based treatments for the Latin American market.
For more information please refer to the Press Release of March 5, 2018